Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3323-8
Abstract: The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis… read more here.
Keywords: related vegf; carfilzomib lenalidomide; response related; response ... See more keywords
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Blood Cancer Journal"
DOI: 10.1038/s41408-020-0297-2
Abstract: Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma Maria… read more here.
Keywords: krd following; carfilzomib lenalidomide; lenalidomide dexamethasone; following asct ... See more keywords
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020007522
Abstract: In this phase 2 multicenter study (NCT01816971), we evaluated incorporation of autologous stem cell transplant (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4… read more here.
Keywords: cycles krd; carfilzomib lenalidomide; newly diagnosed; multiple myeloma ... See more keywords
Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.16145
Abstract: Background/Aim: Carfilzomib, lenalidomide, and dexamethasone (KRD) therapy is widely used for patients with relapse/refractory multiple myeloma (RRMM). However, the response in patients who underwent assessment for measurable residual disease (MRD) has not been elucidated in… read more here.
Keywords: krd; krd therapy; mrd; response ... See more keywords
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15030955
Abstract: Simple Summary Cardiotoxicity is a known adverse effect of Carfilzomib therapy; nevertheless, limited data are available on the comparison of the cardiovascular complications induced by Carfilzomib-dexamethasone versus Carfilzomib-lenalidomide-dexamethasone in patients with multiple myeloma (MM) in… read more here.
Keywords: carfilzomib; dexamethasone; incidence; carfilzomib dexamethasone ... See more keywords